NAIGX
Price
$42.28
Change
+$0.45 (+1.08%)
Updated
Aug 21 closing price
Net Assets
1.25B
VIHAX
Price
$50.90
Change
+$0.55 (+1.09%)
Updated
Aug 21 closing price
Net Assets
21.87B
Interact to see
Advertisement

NAIGX vs VIHAX

NAIGX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
NAIGX vs. VIHAX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAIGX is a Hold and VIHAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 21.9B vs. NAIGX (1.25B). VIHAX pays higher dividends than NAIGX: VIHAX (3.45) vs NAIGX (0.01). NAIGX was incepted earlier than VIHAX: NAIGX (27 years) vs VIHAX (10 years). NAIGX (1.29) is less costly to investors than VIHAX (0.16). NAIGX is a more actively managed with annual turnover of: 28.00 vs. VIHAX (9.00). NAIGX has a lower initial minimum investment than VIHAX: NAIGX (2500) vs VIHAX (3000). VIHAX annual gain was more profitable for investors over the last year : 25.96 vs. NAIGX (21.82). NAIGX return over 5 years is better than : 77.93 vs. VIHAX (66.41).
NAIGXVIHAXNAIGX / VIHAX
Total Expense Ratio1.150.16719%
Annual Report Gross Expense Ratio1.290.16806%
Fund Existence27 years10 years-
Gain YTD12.41717.60171%
Front Load6%N/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets1.25B21.9B6%
Annual Yield % from dividends0.013.450%
Returns for 1 year21.8225.9684%
Returns for 3 years71.1775.6394%
Returns for 5 years77.9366.41117%
Returns for 10 years123.76108.07115%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMOCX19.250.23
+1.21%
Victory RS Mid Cap Growth C
CIVHX22.290.17
+0.77%
American Funds Intl Vntg 529-F-3
GSYPX45.930.22
+0.48%
Goldman Sachs Small Cap Value P
PASTX68.290.18
+0.26%
T. Rowe Price Science & Tech Adv
JMNCX12.25-0.01
-0.08%
JPMorgan Research Market Neutral C